Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A nonsteroidal aromatase inhibitor (AI) and a Cyclin-dependent kinase 4 (CDK4) inhibitors / Cyclin-dependent kinase 6 (CDK6) inhibitors should be offered to postmenopausal women with treatment-naıve Breast Cancer / Mammacarcinoma (HR+). For example, Fulvestrant and a CDK4/6 inhibitor should be offered to patients with progressive disease during treatment with Aromatase Inhibitors (or who develop a recurrence within 1 year of adjuvant AI therapy) with or without one line of prior chemotherapy for metastatic dis…